Use Of 5α-Reductase Inhibitors And Survival Of Esophageal And Gastric Cancer In A Nationwide Swedish Cohort Study

May 2023 in “ Acta Oncologica ”

Sirus Rabbani, Fredrik Mattsson, Jesper Lagergren, Shao‐Hua Xie

TLDR 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.

This nationwide Swedish cohort study investigated the impact of 5α-reductase inhibitors (5-ARIs) on the survival of patients who underwent curatively intended treatment for oesophago-gastric cancer. The study concluded that there was no evidence to support the hypothesis that the use of 5-ARIs improved survival rates in these patients.

View this study on tandfonline.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

An Observational Retrospective Evaluation of 79 Young Men with Long-Term Adverse Effects After Use of Finasteride Against Androgenetic Alopecia

research An Observational Retrospective Evaluation of 79 Young Men with Long-Term Adverse Effects After Use of Finasteride Against Androgenetic Alopecia

43 citations , January 2016 in “International Journal of Andrology”

Finasteride caused long-term sexual and non-sexual side effects in young men with hair loss.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

research 5α-Reductase Activity in the Prostate

237 citations , December 2001 in “Urology”

Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.